

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645
Jlw

Applicant: Kevin M. Slawin et al.

Title: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER

Docket No.: 675.002US1

Filed: February 7, 2002

Serial No.: 10/071,861



Examiner: Unknown

Due Date: N/A

Group Art Unit: 1645


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 5 cited documents.
- ☒ Partial International Search Report (7 pgs.).
- ☒ A return postcard.

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: 
Atty: Janet E. Embreison
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20 day of May, 2004.

Peter Rebuffoni
Name

Peter Rebuffoni
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.



US/N 10/071,861

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kevin M. Slawin et al.	Examiner:	Unknown
Serial No.:	10/071,861	Group Art Unit:	1645
Filed:	February 07, 2002	Docket:	675.002US1
Title:	METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The attached references were discovered in part as the result of a Partial International Search Report in a related copending foreign patent application. Enclosed for the Examiner's information is a copy of the references and the Partial International Search Report.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/071861

Filing Date: February 07, 2002

Title: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER

Page 2

Dkt: 675.002US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.


Respectfully submitted,

KEVIN M. SLAWIN ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959


Date May 20, 2004

By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20 day of May, 2004.

Peter Rebuffoni
Name

Peter Pahn
Signature



Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/071861
Filing Date	February 7, 2002
First Named Inventor	Slawin, Kevin
Group Art Unit	1645
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 675.002US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	WO 02/31209A	04/18/2002	Mousses, S., et al.	C12Q	1/68	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOK, R. A., et al., "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of outcome in Hormone-Refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study", <u>Cancer Research</u> , 61(6), (March 15, 2001), pp. 2533-2536	
		DUQUE, J. L., et al., "Plasma Levels of Vascular Endothelial Growth Factor are Increased in Patients with metastatic Prostate Cancer", <u>Urology</u> , 54(3), (September 1999), pp. 523-527	
		GEORGE, D. J., et al., "Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-Refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480", <u>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</u> , 7(7), (July 2001), pp. 1932-1936	
		JONES, A., et al., "Elevated Serum Vascular Endothelial Growth Factor in Patients with Hormone-Escaped Prostate Cancer", <u>BJU International</u> , 85(3), (February 2000), pp. 276-280	

EXAMINER

DATE CONSIDERED